We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Coronavirus Vaccine Sales Key to Moderna's (MRNA) Q3 Earnings
Read MoreHide Full Article
Moderna, Inc. (MRNA - Free Report) received the first emergency use authorization (“EUA”) for its COVID-19 vaccine, mRNA-1273, for adults in December 2020 in the United States. The vaccine has boosted the company’s top line significantly in the past two quarters. The Zacks Consensus Estimate for third-quarter revenues is pegged at $6.09 billion.
During the third quarter, a booster or “third” dose of the company’s COVID-19 vaccine was authorized for use in immunocompromised adults in the United States and Europe. The initial two-dose regimen of the vaccine was authorized for use in adolescents in Europe during the quarter as well. The vaccine was also authorized for use in adults in a few new countries in the third quarter. These are likely to have aided sales in the soon-to-be reported quarter.
The booster dose of mRNA-1273 was authorized in the United States last month for use in adults at high risk of COVID-19 infections. The company may provide an updated guidance to include future revenues from booster doses on its third-quarter earnings call.
Moderna is seeking EUA for the use of its vaccine adolescents in the United States. However, the FDA had notified last week that additional time would be required to review the EUA request for evaluating the increased risk of myocarditis related to the vaccine. Moderna decided to delay its filing of a EUA request for the use of its vaccine in children aged 6 to less than 12 years. Investors are likely to ask questions on the impact of these delays on near-term growth.
We note that Pfizer (PFE - Free Report) , in collaboration with BioNTech (BNTX - Free Report) , J&J and AstraZeneca (AZN - Free Report) are companies with an authorized/approved coronavirus vaccine. Several other vaccines for COVID-19 are in development and are expected to get approval soon. The company may discuss competition following the anticipated delay in getting EUA for the new population on its third-quarter earnings call.
The company has received a commitment of approximately $1.3 billion from the U.S. government's Operation Warp Speed program and BARDA. These funds will be available to the company as and when needed as grants or awards. The company used a significant amount of funding and was left with $421 million at the end of the second quarter. The company may have used the remaining fund to submit different EUA requests and a complete approval request for mRNA-1273 in the United States. The Zacks Consensus Estimate for grant revenues is pegged at $82 million.
Moderna’s stock has skyrocketed 402.4% so far this year against a decrease of 1.3% for the industry.
Image Source: Zacks Investment Research
Moderna has a few strategic alliances with pharma companies for the development of some of its pipeline candidates. These alliances generate collaboration revenues for the company. The Zacks Consensus Estimate for collaboration revenues is pegged at $16.55 million for the third quarter.
Apart from mRNA-1273, Moderna is engaged in developing several other mRNA-based products targeting a wide variety of diseases. During the third quarter, the company initiated three new phase I/II studies to evaluate a flu vaccine candidate, an autoimmune therapeutic candidate and an investigational mRNA therapeutic for methylmalonic acidemia. The company initiated a phase III study in October to evaluate its cytomegalovirus vaccine candidate. The company is also conducting clinical studies on its COVID-19 vaccine to develop it for new population or variant-specific booster doses. The company is also focused on capacity expansion to support manufacturing and supply of its COVID-19 vaccine and booster doses, and other mRNA-based pipeline candidates.
These ongoing clinical studies, preparation for the late-stage CMV vaccine study, and capacity expansion are likely to have driven operating expense higher for the company during the third quarter. (Read more: Moderna to Report Q3 Earnings: What's in the Cards?)
Image: Bigstock
Coronavirus Vaccine Sales Key to Moderna's (MRNA) Q3 Earnings
Moderna, Inc. (MRNA - Free Report) received the first emergency use authorization (“EUA”) for its COVID-19 vaccine, mRNA-1273, for adults in December 2020 in the United States. The vaccine has boosted the company’s top line significantly in the past two quarters. The Zacks Consensus Estimate for third-quarter revenues is pegged at $6.09 billion.
During the third quarter, a booster or “third” dose of the company’s COVID-19 vaccine was authorized for use in immunocompromised adults in the United States and Europe. The initial two-dose regimen of the vaccine was authorized for use in adolescents in Europe during the quarter as well. The vaccine was also authorized for use in adults in a few new countries in the third quarter. These are likely to have aided sales in the soon-to-be reported quarter.
The booster dose of mRNA-1273 was authorized in the United States last month for use in adults at high risk of COVID-19 infections. The company may provide an updated guidance to include future revenues from booster doses on its third-quarter earnings call.
Moderna is seeking EUA for the use of its vaccine adolescents in the United States. However, the FDA had notified last week that additional time would be required to review the EUA request for evaluating the increased risk of myocarditis related to the vaccine. Moderna decided to delay its filing of a EUA request for the use of its vaccine in children aged 6 to less than 12 years. Investors are likely to ask questions on the impact of these delays on near-term growth.
We note that Pfizer (PFE - Free Report) , in collaboration with BioNTech (BNTX - Free Report) , J&J and AstraZeneca (AZN - Free Report) are companies with an authorized/approved coronavirus vaccine. Several other vaccines for COVID-19 are in development and are expected to get approval soon. The company may discuss competition following the anticipated delay in getting EUA for the new population on its third-quarter earnings call.
The company has received a commitment of approximately $1.3 billion from the U.S. government's Operation Warp Speed program and BARDA. These funds will be available to the company as and when needed as grants or awards. The company used a significant amount of funding and was left with $421 million at the end of the second quarter. The company may have used the remaining fund to submit different EUA requests and a complete approval request for mRNA-1273 in the United States. The Zacks Consensus Estimate for grant revenues is pegged at $82 million.
Moderna’s stock has skyrocketed 402.4% so far this year against a decrease of 1.3% for the industry.
Moderna has a few strategic alliances with pharma companies for the development of some of its pipeline candidates. These alliances generate collaboration revenues for the company. The Zacks Consensus Estimate for collaboration revenues is pegged at $16.55 million for the third quarter.
Apart from mRNA-1273, Moderna is engaged in developing several other mRNA-based products targeting a wide variety of diseases. During the third quarter, the company initiated three new phase I/II studies to evaluate a flu vaccine candidate, an autoimmune therapeutic candidate and an investigational mRNA therapeutic for methylmalonic acidemia. The company initiated a phase III study in October to evaluate its cytomegalovirus vaccine candidate. The company is also conducting clinical studies on its COVID-19 vaccine to develop it for new population or variant-specific booster doses. The company is also focused on capacity expansion to support manufacturing and supply of its COVID-19 vaccine and booster doses, and other mRNA-based pipeline candidates.
These ongoing clinical studies, preparation for the late-stage CMV vaccine study, and capacity expansion are likely to have driven operating expense higher for the company during the third quarter. (Read more: Moderna to Report Q3 Earnings: What's in the Cards?)
Moderna, Inc. Price and EPS Surprise
Moderna, Inc. price-eps-surprise | Moderna, Inc. Quote
Zacks Rank
Moderna currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.